Amantadine

Generic Name: Amantadine

Brand Names: Gocovri, Osmolex

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N

CAS Number: 768-94-5

Unique Ingredient Identifier: BF4C9Z1J53

Background: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps ...

Indication: For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions: Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism

Associated Therapies: -

Clinical Trials

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Phase 2

Recruiting

Conditions: Long COVID
Post-Acute COVID-19 Syndrome

Interventions: Drug: Amantadine
Other: Provider Counseling
Other: Physical, Occupational, Speech Therapy
Other: Medications for symptoms management

First Posted Date: 2024-01-31

Last Posted Date: 2024-10-30

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 30

Registration Number: NCT06234462

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Amantadine Therapy for Cognitive Impairment in Long COVID

Phase 1

Recruiting

Conditions: Long COVID
Post-COVID19 Condition
Post-Acute COVID19 Syndrome

Interventions: Drug: Amantadine

First Posted Date: 2023-09-26

Last Posted Date: 2024-03-07

Lead Sponsor: Ohio State University

Target Recruit Count: 60

Registration Number: NCT06055244

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

The Effect of Amantadine on Post-COVD-19 Fatigue

Phase 2

Not yet recruiting

Conditions: Post-COVID-19 Syndrome

Interventions: Drug: Amantadine

First Posted Date: 2022-12-28

Last Posted Date: 2022-12-28

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 83

Registration Number: NCT05667077

Locations: 🇮🇷
Shohada Tajrish Hospital, Tehran, Iran, Islamic Republic of

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

Recruiting

Conditions: COVID-19

Interventions: Drug: Antihistamine
Drug: Amantadine

First Posted Date: 2022-08-17

Last Posted Date: 2024-04-26

Lead Sponsor: Consorci Sanitari de Terrassa

Target Recruit Count: 170000

Registration Number: NCT05504057

Locations: 🇪🇸
Hospital de Terrassa, Terrassa, Barcelona, Spain
🇪🇸
Hospital of Terrassa, Terrassa, Barcelona, Spain

Amantadine for Neuroenhancement in Acute Patients Study

Phase 2

Recruiting

Conditions: Disorder of Consciousness

Interventions: Drug: Amantadine

First Posted Date: 2022-07-28

Last Posted Date: 2024-02-01

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 50

Registration Number: NCT05479032

Locations: 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany

Promoting Recovery After STroke With Amantadine

Phase 2

Recruiting

Conditions: Stroke, Ischemic
Stroke Hemorrhagic

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2021-12-01

Last Posted Date: 2024-02-21

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 60

Registration Number: NCT05140148

Locations: 🇺🇸
The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Efficacy of Amantadine Treatment in COVID-19 Patients

Phase 3

Terminated

Conditions: Patients With Moderate or Severe COVID-19

Interventions: Drug: Amantadine

First Posted Date: 2021-07-07

Last Posted Date: 2022-09-30

Lead Sponsor: Noblewell

Target Recruit Count: 193

Registration Number: NCT04952519

Locations: 🇵🇱
Tymczasowy Szpital Narodowy, CSK MSWiA, Warsaw, Poland
🇵🇱
Szpital Tymczasowy Zespół Opieki Zdrowotnej, Bolesławiec, Poland
🇵🇱
Oddział gruźlicy i chorób płuc; Lubuski Szpital Specjalistyczny Pulmonologiczno-Kardiologiczny w Torzymiu Spółka z o.o., Torzym, Poland

and more 9 locations

Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Phase 4

Recruiting

Conditions: Treatment Resistant Depression

Interventions: Drug: Quetiapine
Drug: Amantadine
Drug: Pramipexole

First Posted Date: 2021-06-23

Last Posted Date: 2023-08-22

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 150

Registration Number: NCT04936126

Locations: 🇮🇳
All India Institute of Medical Sciences, Bhubaneswar, Orissa, India

Amantadine for COVID-19

Phase 3

Conditions: Covid19

Interventions: Drug: Lactose monohydrate
Drug: Amantadine

First Posted Date: 2021-05-20

Last Posted Date: 2021-10-06

Lead Sponsor: Copenhagen University Hospital, Hvidovre

Target Recruit Count: 226

Registration Number: NCT04894617

Locations: 🇩🇰
Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark

Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: GOCOVRI

First Posted Date: 2020-05-14

Last Posted Date: 2024-10-10

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 8

Registration Number: NCT04387773

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy